ALPHA-ADRENOCEPTOR VASCULAR FUNCTION IN CHRONIC KIDNEY DISEASE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是更多地了解为什么大多数早期肾病患者患有高血压。 我们知道，身体产生的天然物质会使血管在需要时张开，以输送更多的血液。一个例子是在锻炼过程中。其他天然物质会导致血管变小，并在需要时减缓血液流动。一个例子是当人们感到寒冷时。这些物质之间的平衡很重要。患有肾病和高血压的人没有这些物质的正常平衡。 这项研究将包括3组人，血压正常的人，高血压的人和肾脏疾病的人。 “受试者将进行筛选体检，包括ECG和实验室检查 “高血压受试者在住院GCRC研究前3周内不得服用常规血压药物 “在住院研究期间，受试者将接受动脉内药物治疗，这将导致血管发生变化。 然后，研究将比较三组的反应。将进行GFR检测，以确认慢性肾脏疾病组的肾功能。 这些研究将提供对进展性肾病受试者血管反应性增强的发病机制的深入了解。这将为在迅速增长的CKD患者群体中治疗和预防血管疾病的新策略奠定基础。'

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to learn more about why most patients with early stages of kidney disease have high blood pressure. We know the body produces natural substances that cause blood vessels to open wider to carry more blood when needed. An example is during exercise. Other natural substances cause blood vessels to get smaller and slow down blood flow when needed. An example is when people are cold. The balance between these substances is important. People with kidney disease and high blood pressure do not have the normal balance of these substances. This study will include 3 groups of people, people with normal blood pressure, people with high blood pressure and people with kidney disease. " Subjects will have a screening physical examination, including an ECG and laboratory tests " Subjects with high blood pressure may not take their regular blood pressure medication for 3 weeks prior to the inpatient GCRC study " Subjects will be given intra-arterial medications that will cause changes in the blood vessels during the in-patient study. The study will then compare the responses of the three groups. A GFR test will be done to confirm the renal function of the group with chronic kidney disease. These studies will provide insight into the mechanisms of the pathogenesis of enhanced ¿1 vasoreactivity in subjects with progressive renal disease. This will lay the groundwork for new strategies in the treatment and prevention of vascular disease among the rapidly growing group of individuals with CKD.'